Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 68.93 Million SEK | 5.92% |
| 2022 | 64.65 Million SEK | 13.45% |
| 2021 | 56.98 Million SEK | 8.16% |
| 2020 | 52.68 Million SEK | 23.29% |
| 2019 | 42.73 Million SEK | 26.15% |
| 2018 | 33.87 Million SEK | 38.42% |
| 2017 | 24.47 Million SEK | -8.71% |
| 2016 | 26.8 Million SEK | 61.83% |
| 2015 | 16.56 Million SEK | -7.22% |
| 2014 | 17.85 Million SEK | -1.61% |
| 2013 | 18.14 Million SEK | 42.38% |
| 2012 | 12.74 Million SEK | 72.77% |
| 2011 | 7.37 Million SEK | 39.89% |
| 2010 | 5.27 Million SEK | 149.66% |
| 2009 | 2.11 Million SEK | 175.47% |
| 2008 | 766.83 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 15.74 Million SEK | -3.51% |
| 2024 Q1 | 16.31 Million SEK | -19.35% |
| 2024 Q3 | - SEK | -97.54% |
| 2023 Q1 | 15.09 Million SEK | 97.26% |
| 2023 Q4 | 20.23 Million SEK | 18.33% |
| 2023 Q2 | 17.09 Million SEK | 13.28% |
| 2023 FY | 68.47 Million SEK | 5.92% |
| 2023 Q3 | 17.09 Million SEK | -0.01% |
| 2022 Q4 | 7.65 Million SEK | -70.79% |
| 2022 Q1 | 13.56 Million SEK | -5.29% |
| 2022 Q2 | 17.23 Million SEK | 27.06% |
| 2022 FY | 64.65 Million SEK | 13.45% |
| 2022 Q3 | 26.19 Million SEK | 51.98% |
| 2021 Q1 | 10.33 Million SEK | -12.63% |
| 2021 Q3 | 12.1 Million SEK | -40.12% |
| 2021 Q4 | 14.32 Million SEK | 18.37% |
| 2021 FY | 56.98 Million SEK | 8.16% |
| 2021 Q2 | 20.2 Million SEK | 95.52% |
| 2020 Q4 | 11.83 Million SEK | 31.63% |
| 2020 Q2 | 10.82 Million SEK | -48.53% |
| 2020 FY | 52.68 Million SEK | 23.29% |
| 2020 Q1 | 21.03 Million SEK | 66.12% |
| 2020 Q3 | 8.98 Million SEK | -17.0% |
| 2019 Q4 | 12.66 Million SEK | 33.77% |
| 2019 FY | 42.73 Million SEK | 26.15% |
| 2019 Q3 | 9.46 Million SEK | -11.14% |
| 2019 Q1 | 9.94 Million SEK | 6.8% |
| 2019 Q2 | 10.65 Million SEK | 7.14% |
| 2018 FY | 33.87 Million SEK | 38.42% |
| 2018 Q1 | 1.29 Million SEK | -73.32% |
| 2018 Q4 | 9.31 Million SEK | 24.63% |
| 2018 Q3 | 7.47 Million SEK | -52.7% |
| 2018 Q2 | 15.79 Million SEK | 1119.42% |
| 2017 FY | 24.47 Million SEK | -8.71% |
| 2017 Q4 | 4.85 Million SEK | -27.24% |
| 2017 Q3 | 6.67 Million SEK | 26.5% |
| 2017 Q2 | 5.27 Million SEK | -31.28% |
| 2017 Q1 | 7.67 Million SEK | 68.59% |
| 2016 FY | 26.8 Million SEK | 61.83% |
| 2016 Q2 | 6.24 Million SEK | -22.81% |
| 2016 Q1 | 8.08 Million SEK | 84.43% |
| 2016 Q3 | 7.91 Million SEK | 26.84% |
| 2016 Q4 | 4.55 Million SEK | -42.5% |
| 2015 Q3 | 3.77 Million SEK | -2.48% |
| 2015 Q4 | 4.38 Million SEK | 16.25% |
| 2015 FY | 16.56 Million SEK | -7.22% |
| 2015 Q2 | 3.86 Million SEK | -14.74% |
| 2015 Q1 | 4.53 Million SEK | -47.51% |
| 2014 FY | 17.85 Million SEK | -1.61% |
| 2014 Q4 | 8.64 Million SEK | 177.39% |
| 2014 Q2 | 3.5 Million SEK | 34.99% |
| 2014 Q3 | 3.11 Million SEK | -11.0% |
| 2014 Q1 | 2.59 Million SEK | -57.93% |
| 2013 Q4 | 6.16 Million SEK | 54.39% |
| 2013 Q2 | 4.33 Million SEK | 18.95% |
| 2013 Q3 | 3.99 Million SEK | -7.98% |
| 2013 FY | 18.14 Million SEK | 42.38% |
| 2013 Q1 | 3.64 Million SEK | -0.85% |
| 2012 Q4 | 3.67 Million SEK | 18.2% |
| 2012 Q2 | 2.45 Million SEK | -30.0% |
| 2012 Q1 | 3.5 Million SEK | 31.48% |
| 2012 FY | 12.74 Million SEK | 72.77% |
| 2012 Q3 | 3.11 Million SEK | 27.07% |
| 2011 Q3 | 1.24 Million SEK | -31.89% |
| 2011 Q2 | 1.82 Million SEK | 10.49% |
| 2011 Q1 | 1.64 Million SEK | 28.37% |
| 2011 Q4 | 2.66 Million SEK | 114.59% |
| 2011 FY | 7.37 Million SEK | 39.89% |
| 2010 Q2 | 1.04 Million SEK | -44.0% |
| 2010 FY | 5.27 Million SEK | 149.66% |
| 2010 Q3 | 1.08 Million SEK | 4.0% |
| 2010 Q1 | 1.86 Million SEK | 284.5% |
| 2010 Q4 | 1.28 Million SEK | 18.4% |
| 2009 Q2 | 394.06 Thousand SEK | -53.63% |
| 2009 Q1 | 849.77 Thousand SEK | 273.58% |
| 2009 FY | 2.11 Million SEK | 175.47% |
| 2009 Q4 | 484.3 Thousand SEK | 26.03% |
| 2009 Q3 | 384.26 Thousand SEK | -2.49% |
| 2008 FY | 766.83 Thousand SEK | 0.0% |
| 2008 Q4 | -489.56 Thousand SEK | -231.43% |
| 2008 Q3 | 372.48 Thousand SEK | -33.18% |
| 2008 Q2 | 557.43 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 16.801% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 88.733% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 88.733% |
| Arcoma AB | 53.25 Million SEK | -29.441% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -1287.201% |
| BICO Group AB (publ) | 2.84 Billion SEK | 97.58% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 67.245% |
| CellaVision AB (publ) | 295.99 Million SEK | 76.712% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -5165.116% |
| C-Rad AB (publ) | 3.8 Million SEK | -1713.947% |
| Duearity AB (publ) | 21.58 Million SEK | -219.342% |
| Dignitana AB (publ) | 74.73 Million SEK | 7.769% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -2452.963% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.359% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -278.143% |
| Iconovo AB (publ) | 63.35 Million SEK | -8.801% |
| Integrum AB (publ) | 90.57 Million SEK | 23.894% |
| Luxbright AB (publ) | 23.09 Million SEK | -198.521% |
| Mentice AB (publ) | 237.06 Million SEK | 70.923% |
| OssDsign AB (publ) | 175.6 Million SEK | 60.746% |
| Paxman AB (publ) | 133.8 Million SEK | 48.483% |
| Promimic AB (publ) | 48.55 Million SEK | -41.971% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 57.551% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 1.495% |
| ScandiDos AB (publ) | 61.03 Million SEK | -12.93% |
| Sectra AB (publ) | 39.06 Million SEK | -76.459% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 60.505% |
| Senzime AB (publ) | 141.51 Million SEK | 51.292% |
| SpectraCure AB (publ) | 12.12 Million SEK | -468.354% |
| Stille AB | 87.21 Million SEK | 20.969% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 98.762% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 84.367% |